Exhibit 99.1 Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update – LOQTORZI net revenue was 10.0million,a3610.0 million, a 36% increase over Q1 2025 – – Data readouts for CHS-114 and casdozokitug on track for 1H 2026 – ● LOQTORZI is the only FDA-approved and available treatment in the U.S. for recurrent, locally advanced or metastatic nasopharyngeal carcinoma (NPC), in all patient subsets and across all lines of therapy. ● LOQTORZI net revenue for Q2 2025 was 10.0million,a3610.0 million, a 36% g ...
erus BioSciences(US:CHRS)2025-08-08 04:53